

Product News

CeraVe

Valeant Pharmaceuticals North America LLC receives The Skin Cancer Foundation (SCF) Seal of Recommendation for 2 products in the CeraVe skin care line. The CeraVe AM Facial Moisturizing Lotion With SPF 30 has earned the daily use SCF seal and the CeraVe SPF 50 Sunscreen Face Lotion has earned the active SCF seal. Products earning the SCF seal have fulfilled strict criteria from photobiologists, and consumers can purchase these products with the added reassurance that they perform as claimed. “We believe that more and more people are becoming aware of the dangers posed by unprotected sun exposure and for these individuals, particularly, the Seal of Recommendation is very meaningful,” said Joe Gordon, general manager of consumer health care at Valeant Pharmaceuticals. Both products are available over-the-counter at major retailers. For more information, visit www.cerave.com.

Differin Gel

Galderma Laboratories, LP, announces approval from the US Food and Drug Administration for over-the-counter use of Differin Gel (adapalene gel 0.1%) for the treatment of acne. “We’re excited to deliver this new level of efficacy without a prescription to consumers, and to bring the first new active ingredient to the category in over 30 years,” said Miles Harrison, president and general manager of Galderma Laboratories. With Differin Gel now available over-the-counter versus by prescription, acne patients will have easier access to this prescription-strength product containing the retinoid adapalene. For more information, visit www.differin.com.

UltraShape Power

Syneron Medical Ltd announces US Food and Drug Administration clearance of UltraShape Power, a noninvasive fat destruction device for reduction of abdominal circumference. UltraShape Power uses pulsed mechanical ultrasound energy to target and destroy fat in both large and small areas and the advanced transducer delivers 20% more energy than its predecessor. UltraShape Power offers patients a 32% reduction in subcutaneous fat thickness. Patients have reported favorable results with little pain. A typical regimen is 3 treatments spaced 2 weeks apart. For more information, visit www.syneron-candela.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.